Beijing Jishuitan Hospital reports the first pimicotinib prescription for TGCT
An oral targeted therapy moves from regulatory approval into clinical use for tenosynovial giant cell tumour.
From approval to clinical use
On 26 March 2026, Dr Xiaohui Niu of Beijing Jishuitan Hospital’s Bone Tumour Department issued what the hospital described as the world’s first prescription for pimicotinib for tenosynovial giant cell tumour (TGCT). The Chinese-developed targeted medicine had received approval from the National Medical Products Administration on 16 December 2025.
The milestone reported in March was therefore the start of prescribing, rather than the date of the original marketing approval.
A systemic option alongside surgery
TGCT can create substantial problems for people with recurrent disease or tumours that cannot be satisfactorily managed surgically. Department director Weifeng Liu described the medicine as a systemic option beyond surgery, with the potential to support more coordinated long-term management.
The report presents oral targeted therapy and surgery as tools that can be considered within an individualised plan. It does not imply that every patient needs drug treatment or that surgery has become unnecessary.
The hospital’s role in development
Beijing Jishuitan Hospital’s Bone Tumour Department led the global multicentre pivotal study supporting pimicotinib’s development. According to the article, that work provided key clinical evidence for Chinese approval and international registration efforts.
At the time of the report, applications in the United States and Europe were being advanced. The hospital’s article distinguishes those applications from the Chinese approval already obtained. Its significance is specific to TGCT and should not be generalised to all rare tumours.